JP2011525902A5 - - Google Patents

Download PDF

Info

Publication number
JP2011525902A5
JP2011525902A5 JP2011515663A JP2011515663A JP2011525902A5 JP 2011525902 A5 JP2011525902 A5 JP 2011525902A5 JP 2011515663 A JP2011515663 A JP 2011515663A JP 2011515663 A JP2011515663 A JP 2011515663A JP 2011525902 A5 JP2011525902 A5 JP 2011525902A5
Authority
JP
Japan
Prior art keywords
pathogen
immune response
subject
composition
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011515663A
Other languages
English (en)
Japanese (ja)
Other versions
JP5712126B2 (ja
JP2011525902A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2009/006260 external-priority patent/WO2009156852A1/en
Publication of JP2011525902A publication Critical patent/JP2011525902A/ja
Publication of JP2011525902A5 publication Critical patent/JP2011525902A5/ja
Application granted granted Critical
Publication of JP5712126B2 publication Critical patent/JP5712126B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011515663A 2008-06-25 2009-06-25 遅延型追加刺激免疫処置に対する迅速な応答 Expired - Fee Related JP5712126B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13314008P 2008-06-25 2008-06-25
US61/133,140 2008-06-25
PCT/IB2009/006260 WO2009156852A1 (en) 2008-06-25 2009-06-25 Rapid responses to delayed booster immunisations

Publications (3)

Publication Number Publication Date
JP2011525902A JP2011525902A (ja) 2011-09-29
JP2011525902A5 true JP2011525902A5 (enExample) 2012-08-09
JP5712126B2 JP5712126B2 (ja) 2015-05-07

Family

ID=41171092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011515663A Expired - Fee Related JP5712126B2 (ja) 2008-06-25 2009-06-25 遅延型追加刺激免疫処置に対する迅速な応答

Country Status (5)

Country Link
US (1) US9421251B2 (enExample)
EP (1) EP2310045A1 (enExample)
JP (1) JP5712126B2 (enExample)
CA (1) CA2729248A1 (enExample)
WO (1) WO2009156852A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2590626E (pt) 2010-07-06 2016-01-26 Glaxosmithkline Biolog Sa Lipossomas com lípidos que têm um valor de pka vantajoso para administração de arn
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
HUE058361T2 (hu) 2010-08-31 2022-07-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogént kódoló RNA bejuttatására
ES2945135T3 (es) 2010-10-11 2023-06-28 Glaxosmithkline Biologicals Sa Plataformas de suministro de antígenos
JP5917682B2 (ja) 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
WO2002080648A2 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
TWI365074B (en) 2004-10-07 2012-06-01 Wyeth Corp Multivalent avian influenza vaccines
EP1814583A2 (en) * 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
AR053833A1 (es) 2005-03-23 2007-05-23 Glaxosmithkline Biolog Sa Composicion inmunogenetica
CA2628379A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adminstration routes for priming/boosting with influenza vaccines
JP2009514850A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
US20080014217A1 (en) 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination

Similar Documents

Publication Publication Date Title
JP2011525902A5 (enExample)
Kim et al. Influenza vaccines: Past, present, and future
JP6308500B2 (ja) 強化された免疫賦活化剤
Alving et al. Adjuvants for human vaccines
Jabbal-Gill Nasal vaccine innovation
Tregoning et al. Adjuvanted influenza vaccines
Levitz et al. Beyond empiricism: informing vaccine development through innate immunity research
Mori et al. The vaccine adjuvant alum inhibits IL‐12 by promoting PI 3 kinase signaling while chitosan does not inhibit IL‐12 and enhances T h1 and T h17 responses
Yusuf et al. Current prospects and future challenges for nasal vaccine delivery
Riese et al. Intranasal formulations: promising strategy to deliver vaccines
Skene et al. Saponin-adjuvanted particulate vaccines for clinical use
Smith et al. Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines
Demirjian et al. Safety and efficacy of neonatal vaccination
CN109364244B (zh) 黏膜佐剂和递送系统
de Haan et al. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration
JP2003523310A (ja) 新規インフルエンザウイルスワクチン組成物
Dehghan et al. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants
TW200722101A (en) Novel composition
JP5712126B2 (ja) 遅延型追加刺激免疫処置に対する迅速な応答
Cheong et al. Epigallocatechin-3-gallate as a novel vaccine adjuvant
Jones et al. Protollin™: a novel adjuvant for intranasal vaccines
JP2015524802A5 (enExample)
JP2015529677A5 (enExample)
Krashias et al. Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer
de Veer et al. New developments in vaccine research—unveiling the secret of vaccine adjuvants